Salix Pharmaceuticals Announces Positive Top Line Results of Balsalazide Tablets Registration Study
RALEIGH, N.C.--(BUSINESS WIRE)--Jun 18, 2007 - SalixPharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the successfulcompletion and outcome of its Phase III registration trial toevaluate the safety and efficacy of a new 1100 mg tabletformulation of balsalazide disodium (balsalazide tablets).Balsalazide disodium is the active ingredient in COLAZAL(R)Capsules 750 mg, an anti-inflammatory dru...Salix Pharmaceuticals Previews Digestive Disease Week 2007
RALEIGH, N.C.--(BUSINESS WIRE)--May 17, 2007 - SalixPharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that results of18 investigator-initiated trials related to the Company's productswill be presented at Digestive Disease Week(R) 2007, which will beheld May 19-24, 2007. Digestive Disease Week is considered thelargest and most prestigious meeting in the world for the GIprofessional. Every...